AI on Drugs: Can Artificial Intelligence Accelerate Drug Development? Evidence from a Large-Scale Examination of Bio-Pharma Firms
The DOI matches its Crossref record; 79 of the 79 references it cites were found in a registry or an index.
Abstract
Advances in artificial intelligence (AI) could potentially reduce the complexities and costs in drug discovery. We conceptualize an AI innovation capability that gauges a firm’s ability to develop, manage, and utilize AI resources for innovation. Using patents and job postings to measure AI innovation capability, we find that it can affect a firm’s discovery of new drug-target pairs for preclinical studies. The effect is particularly pronounced for developing new drugs whose mechanism of impact on a disease is known and for drugs at the medium level of chemical novelty. However, AI is less helpful in developing drugs when there is no existing therapy. AI is also less helpful for drugs that are either entirely novel or those that are incremental “followon” drugs. Examining AI skills, a key component of AI innovation capability, we find that the main effect of AI innovation capability comes from employees possessing the combination of AI skills and domain expertise in drug discovery as opposed to employees possessing AI skills only. Having the combination is key because developing and improving AI tools is an iterative process requiring synthesizing inputs from both AI and domain experts during both the development and the operational stages of the tool. Taken together, our study sheds light on both the advantages and the limitations of using AI in drug discovery and how to effectively manage AI resources for drug development.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Artificial intelligence capability is increasingly a critical and intangible resource for business performance advancement (Belhadi et al., 2021; Lou and Wu, 2021; Mikalef and Gupta, 2021).”
From The Impact of Artificial Intelligence on Firm Performance: An Application of the Resource-Based View to e-Commerce Firms (2022) · cites this paper as Lou and Wu, 2021
Citations
Cites
Firm Resources and Sustained Competitive Advantage
Barney, J. (1991) · Journal of Management · doi:10.1177/014920639101700108 · Cited by 48,334 · cited 2×
“Lastly, AI-enabled intangibles, including firm practices and knowledge assets that can empower and foster the use of AI, are key drivers for improving firm performance and competitiveness (Barney 1991; Teece 1998).”
Squeeze-and-Excitation Networks
Hu, J., Shen, L., & Sun, G. (2018) · 2018 IEEE/CVF Conference on Computer Vision and Pattern Recognition · doi:10.1109/cvpr.2018.00745 · Cited by 35,667
The central role of the propensity score in observational studies for causal effects
ROSENBAUM, P. R., & RUBIN, D. B. (1983) · Biometrika · doi:10.1093/biomet/70.1.41 · Cited by 31,241 · cited 3×
“…the Propensity Score Matching (PSM) and Coarsened Exact Matching (CEM) method to match AI and non-AI firms based on the firm characteristics including financial ownership status, firm age, total number of employees and R&D expenses (Blackwell et al. 2009; Ho et al. 2007; Rosenbaum and Rubin 1983).”
Delving Deep into Rectifiers: Surpassing Human-Level Performance on ImageNet Classification
He, K., Zhang, X., Ren, S., & Sun, J. (2015) · 2015 IEEE International Conference on Computer Vision (ICCV) · doi:10.1109/iccv.2015.123 · Cited by 19,741 · cited 1×
“Through many examples of input-output pairs, supervised learning (an area of machine learning) can accurately uncover linkages and make better and faster predictions than humans can in many areas (He et al. 2015; Hu et al. 2018).”
Endogenous Technological Change
Romer, P. M. (1990) · Journal of Political Economy · doi:10.1086/261725 · Cited by 17,711
Squeeze-and-Excitation Networks
Hu, J., Shen, L., Albanie, S., Sun, G., & Wu, E. (2020) · IEEE Transactions on Pattern Analysis and Machine Intelligence · doi:10.1109/tpami.2019.2913372 · Cited by 12,157
The resource-based theory of competitive advantage: Implications for strategy formulation
Grant, R. M. (1991) · California Management Review · doi:10.2307/41166664 · Cited by 9,699 · cited 2×
“…use, and manage AI resources in combination or co-present with other resources and capabilities to effectively conduct scientific discovery and R&D. Grant (1991) suggests that firms can leverage three types of resources to create competitive advantage: tangible resources, personnel-based…”
DrugBank 5.0: a major update to the DrugBank database for 2018
Wishart, D. S., Feunang, Y. D., Guo, A. C., Lo, E. J., Marcu, A., Grant, J. R., Sajed, T., Johnson, D., Li, C., Sayeeda, Z., et al. (2018) · Nucleic Acids Research · doi:10.1093/nar/gkx1037 · Cited by 8,404 · cited 2×
“We also use the free text in the DrugBank database that contains comprehensive information about how each drug works (Wishart et al. 2018; Wishart et al. 2008) to ascertain the drug mechanism.2”
Weininger, D. (1988) · Journal of Chemical Information and Computer Sciences · doi:10.1021/ci00057a005 · Cited by 7,436 · cited 1×
“Our drug data provide the simplified molecular-input line-entry system (SMILES) code, which is a chemical notation language mainly designed for digital processing (Weininger 1988).”
Bharadwaj, A. S. (2000) · MIS Quarterly · doi:10.2307/3250983 · Cited by 5,042 · cited 5×
“AI Innovation Capability and the Resource-based View of the Firm Firms have developed IT capabilities to gain competitive advantage (Bharadwaj 2000; Santhanam and Hartono 2003).”
Influential
Research works printed but not linked: 11
- Abrams, 2017, What’s the Value of Patent Citations? Evidence from Pharmaceuticals, Working Paper
- Agrawal, 2019, Artificial Intelligence, Scientific Discovery, and Commercial Innovation, Working Paper
- Du Plessis, 2009, Data Production Methods for Harmonized Patent Indicators: Assignee Sector Allocation
- Hitt, 2018, Corporate Data Literacy: Scoring Firms and Firm Performance, IHS Markit White Paper
- Johnson, 1990, Concepts and Applications of Molecular Similarity
- Jones, 2005, Growth and Ideas, 1063
- Marcus, 2019, Rebooting AI: Building Artificial Intelligence We Can Trust
- 2010, Mechanism Matters, Nature Medicine, 16, 347, 10.1038/nm0410-347) · DOI
- Pisano, 2006, Science Business: The Promise, the Reality, and the Future of Biotech
- Raymond, 2019, The AI Index 2019 Annual Report, AI Index Steering Committee, Human-Centered AI Institute, Stanford University
- Trafton, 2020, Artificial Intelligence Yields New Antibiotic, MIT News
Cited by
Managing artificial intelligence
Berente, N., Gu, B., Recker, J., & Santhanam, R. (2021) · MIS Quarterly · doi:10.25300/misq/2021/16274 · Cited by 898
Gama, F., & Magistretti, S. (2025) · Journal of Product Innovation Management · doi:10.1111/jpim.12698 · Cited by 388
The Crowdless Future? Generative AI and Creative Problem-Solving
Boussioux, L., Lane, J. N., Zhang, M., Jacimovic, V., & Lakhani, K. R. (2024) · Organization Science · doi:10.1287/orsc.2023.18430 · Cited by 329
Chen, D., Esperança, J. P., & Wang, S. (2022) · Frontiers in Psychology · doi:10.3389/fpsyg.2022.884830 · Cited by 198
“Artificial intelligence capability is increasingly a critical and intangible resource for business performance advancement (Belhadi et al., 2021; Lou and Wu, 2021; Mikalef and Gupta, 2021).”
BackgroundManaging with Artificial Intelligence: An Integrative Framework
Hillebrand, L., Raisch, S., & Schad, J. (2025) · Academy of Management Annals · doi:10.5465/annals.2022.0072 · Cited by 254
Metadata
- Authors
- Lou, B., & Wu, L.
- Affiliations
- University of Connecticut (US)
- University of Pennsylvania (US)
- ORCID
- Venue
- MIS Quarterly
- Publisher
- MIS Quarterly
- Published
- 2021-09-01
- Volume
- 45
- Issue
- 3
- Pages
- 1451-1482
- ISSN
- 0276-7783 (ISSN-L)
- 2162-9730
- OpenAlex
- W3200787894
- Cited by
- 177
- References
- 78
- Citations by year
- 2026: 53 · 2025: 58 · 2024: 34 · 2023: 19 · 2022: 10 · 2021: 3
- FWCI
- 8.70
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- MIS Quarterly (publishedVersion)
- Journal of the Association for Information Systems (submittedVersion)
- Topics
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Drug Discovery › Computational Drug Discovery Methods
- Social Sciences › Business, Management and Accounting › Strategy and Management › Innovation and Knowledge Management
- Social Sciences › Economics, Econometrics and Finance › Economics and Econometrics › Pharmaceutical Economics and Policy
- Keywords
- artificial intelligence, drug discovery, drug development, biopharmaceutical firms, AI competencies, domain knowledge, follow-on drugs, patents, job advertisements
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.